Denis Katz Medical Affairs
Today, central nervous system (CNS) disorders are being redefined through molecular signatures, circuit-level dysfunction, and continuously captured digital phenotypes. This shift is not incremental it fundamentally alters how therapies must be discovered, developed, and approved.
https://salienceclinical.com/

Salience Clinical Consulting
Cell-based therapies and advanced biologics are redefining what is possible in the treatment of neurological disease. Unlike traditional pharmacologic approaches, these modalities aim to directly influence disease biology through neuronal replacement, gene correction, immune modulation, or sustained protein expression.
https://salienceclinical.com/

Salience Clinical, LLC
A significant proportion of patients remain treatment resistant. Among those who respond, relapse is frequent. Incremental gains from traditional pharmacology are becoming harder to achieve, suggesting that synaptic modulation alone may no longer be sufficient to meaningfully shift long-term outcomes.
https://salienceclinical.com/

Denis Katz Medical Affairs
Alzheimer’s disease (AD) drug development remains the most capital-intensive and failure-prone domain in biopharma. The so-called “Alzheimer’s graveyard” reflects decades of scientific promise undermined by regulatory, operational, and strategic misalignment.
https://salienceclinical.com/

Denis Katz Clinical Consultant

Salience Clinical operates at the convergence of neuroscience, regulatory science, and precision strategy—helping sponsors translate biological complexity into approvable labels, defensible value, and durable market position.
https://salienceclinical.com/